Clinical Trial Update: Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dosimetry-guided PRRT with 90Y-DOTATOC in neuroendocrine tumors and meningioma; trial completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma
• Neuroendocrine Tumors

Drugs mentioned

• 90Y-DOTA-tyr3-octreotide (90Y-DOTA-tyr3-octreotide)

Snippet

Sponsor: University of Iowa | Conditions: Neuroendocrine Tumors, Meningioma | Phase 2 | Status: COMPLETED | Results posted: 2023-02-09